Molefi Thulo, Mabonga Lloyd, Hull Rodney, Sebitloane Motshedisi, Dlamini Zodwa
Discipline of Obstetrics and Gynaecology, School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP), Pan African Research Institute (PACRI), University of Pretoria, Pretoria, South Africa.
Front Oncol. 2025 Jul 9;15:1581645. doi: 10.3389/fonc.2025.1581645. eCollection 2025.
The advent of artificial intelligence (AI) in oncology has opened new avenues for enhancing the diagnosis, treatment, and prognosis of type II endometrial cancers (ECs), which account for the majority of EC-related deaths globally. With rising incidence and increasing concerns in Africa, type II ECs are often detected in advanced stages, exhibit aggressive progression, and resist conventional therapies. Despite these characteristics, they are still treated similarly to type I ECs, which are less aggressive and more treatment-responsive. Currently, no specific targeted therapies exist for type II ECs, creating an urgent need for innovative treatment options.
This review examines the integration of AI-powered approaches in the care of type II ECs, focusing on their potential to address rising incidence and disparities in Africa. It explores AI-driven diagnostic tools, tailored therapeutic options, and ongoing innovative projects, including efforts to integrate indigenous knowledge into AI applications.
AI-powered therapeutic options tailored to the unique clinical profiles of type II EC patients show promise for developing targeted therapies. Several innovative projects are underway, leveraging AI to meet Africa's unique healthcare challenges. These applications demonstrate significant potential to reduce healthcare disparities and improve patient outcomes, especially in resource-limited settings.
This review highlights the transformative potential of AI technologies in improving the diagnosis, treatment and management of type II ECs, particularly in Africa, where healthcare disparities are significant. Through the integration of AI in the type II EC care continuum, challenges in African healthcare can be overcome. Innovative projects, leveraging AI to meet the continent's challenges, have the potential to improve patient outcomes. AI-driven therapies hold the key to personalized oncologic care, and indigenous African knowledge can be used to develop Afrocentric healthcare solutions. In Future, with continued research and the development of robust frameworks and transparent algorithms, investment and collaboration, the potential of AI in Type II EC will be realized.
人工智能（AI）在肿瘤学领域的出现为改善II型子宫内膜癌（EC）的诊断、治疗和预后开辟了新途径，II型子宫内膜癌在全球EC相关死亡中占大多数。随着非洲发病率的上升和关注度的增加，II型EC往往在晚期被发现，具有侵袭性进展，并且对传统疗法耐药。尽管有这些特征，但它们的治疗方式仍与I型EC相似，而I型EC侵袭性较小，对治疗反应更好。目前，II型EC没有特定的靶向治疗方法，因此迫切需要创新的治疗选择。
本综述探讨了人工智能驱动的方法在II型EC护理中的整合，重点关注其应对非洲发病率上升和差异的潜力。它探讨了人工智能驱动的诊断工具、量身定制的治疗选择以及正在进行的创新项目，包括将本土知识整合到人工智能应用中的努力。
针对II型EC患者独特临床特征量身定制的人工智能驱动的治疗选择显示出开发靶向治疗的前景。正在进行几个创新项目，利用人工智能应对非洲独特的医疗挑战。这些应用显示出减少医疗差距和改善患者预后的巨大潜力，特别是在资源有限的环境中。
本综述强调了人工智能技术在改善II型EC的诊断、治疗和管理方面的变革潜力，特别是在非洲，那里的医疗差距很大。通过将人工智能整合到II型EC护理连续过程中，可以克服非洲医疗保健中的挑战。利用人工智能应对非洲大陆挑战的创新项目有可能改善患者预后。人工智能驱动的疗法是个性化肿瘤护理的关键，非洲本土知识可用于开发以非洲为中心的医疗保健解决方案。未来，随着持续的研究以及强大框架和透明算法的开发、投资和合作，人工智能在II型EC中的潜力将得以实现。
